Sign in
4

Changes in Ownership

Spyre Therapeutics, Inc. Filed Acc 0001140361-18-009074

Interim CEO acquired 15,211 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Quinn Anthony G. · Interim CEO

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2018-02-15 Exercise or conversion : show line 1 in the form +15,211 $5.46 $83,052 50,620 D

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2018-02-15 Exercise or conversion : show line 2 in the form Director Stock Option (right to buy) −15,211 8,598 D
Loading xslF345X03/doc1.xml…